Remoxipride

Remoxipride
Systematic (IUPAC) name
	(S)-3-bromo-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxy-benzamide
Clinical data
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Identifiers
CAS number	117591-79-4
ATC code	N05AL04
PubChem	CID 54477
DrugBank	DB00409
ChemSpider	49195
UNII	0223RD59PE
KEGG	D02683
ChEMBL	CHEMBL22242
Chemical data
Formula	C16H23BrN2O3
Mol. mass	371.27 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)/t11-/m0/s1 ; Key:GUJRSXAPGDDABA-NSHDSACASA-N ;
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Remoxipride (Roxiam) is an atypical antipsychotic which was previously used in Europe for the treatment of schizophrenia but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).^[1] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.^[1] Remoxipride acts as a selective D₂ and D₃ receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.^[2]

[edit] See also

^ ^a ^b José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
^ Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990). "Biochemical pharmacology of the atypical neuroleptic remoxipride". Acta Psychiatrica Scandinavica. Supplementum 358: 27–36. PMID 1978484.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.